With the right genomic data we can conquer cancer.

Liquid biopsy is emerging as means to overcome the limits of tissue biopsy for precision medicine due to low invasiveness and high accessibility compared to tissue biopsy and that the fact samples are available at every stage.

Current diagnostic plans for cancer patients are inadequate for minimal residual disease detection, recurrence monitoring, treatment selection and treatment response monitoring. Also there are very few genomic analysis tools that clinicians are willing to use.

Genopeaks will provide a liquid biopsy genome analysis total solution by combining high sensitivity mutation amplification technic with NGS(Next Generation Sequencing) platform.